HEPA — Hepion Pharmaceuticals, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1583771 ·
Last close
$0.12
Market Cap
$10.38M
52W High
$0.22
52W Low
$0.03
ADV30
32,000
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,211,491 | -1,248,237 | 1,927,442 | 1,628,625 | 648,923 |
| Mar 2026 | 0 | — | -798,509 | -810,791 | 2,705,503 | 2,602,580 | 848,747 |
| Dec 2025 | 0 | — | -609,683 | -656,885 | 3,069,952 | 1,828,062 | 402,405 |
| Sep 2025 | 0 | — | -527,902 | -472,506 | 3,740,240 | 2,321,078 | 415,808 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,594,109
Investing CF
$0
Financing CF
$298,339
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.28
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-248,156,684
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-7,650,237
Pretax Income TTM
$-3,188,419
Interest Exp TTM
$26,940
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -3,760,945 | -8,277,850 | 3,069,952 | 402,405 | 2,667,547 | -3,271,520 |
| Dec 2024 | 0 | -19,346,578 | -13,192,420 | 1,613,737 | 3,477,075 | -1,863,338 | -18,216,303 |
| Dec 2023 | 0 | -45,257,954 | -48,926,042 | 18,094,397 | 10,813,590 | 7,280,807 | -40,888,878 |
| Dec 2022 | 0 | -43,617,802 | -42,200,049 | 60,244,452 | 10,388,515 | 49,855,937 | -34,961,171 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-3,188,419
OpCashFlow TTM
—
Assets (Latest)
$1,927,442
Forward EPS
$-11.43
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QNTM | Quantum Biopharma Ltd. | $10.22M | $1.59 | — |
| HIND | Vyome Holdings, Inc | $10.84M | $1.54 | — |
| RADX | Radiopharm Theranostics Ltd | $9.70M | $0.67 | — |
| BIVI | BIOVIE INC. | $9.61M | $1.00 | — |
| LSTA | LISATA THERAPEUTICS, INC. | $11.24M | $1.04 | — |
News headlines (Yahoo Finance, 1h cache)
Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest
2026-10-26 12:01 · Yahoo
Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
2026-10-19 12:01 · Yahoo
Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
2026-10-14 12:01 · Yahoo
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
2026-03-03 12:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.